Spinocerebellar ataxia: 2026 so far

A 12-month randomized SCA3 medicine trial reported benefit.

In the months covered, the strongest medicine evidence came from a randomized, placebo-controlled 12-month trial in SCA3. In that trial, oral DL-3-n-butylphthalide (NBP) led to greater improvement on standard ataxia rating scales than placebo. The same report noted no serious adverse events and similar overall side effects between groups. By comparison, a smaller triple-blind crossover (each person receives both treatments at different times) SCA3 trial of Astragalus did not show a statistically significant difference versus placebo on its main outcome, neurofilament light (a blood or spinal-fluid marker of nerve cell injury), even though there was a slight decrease during the Astragalus period. Taken together, the 2026 reports to date put the most direct human drug evidence on NBP in SCA3, while other symptom-medicine signals were weaker or limited to very small observations.

Research covered in: September 2026

Evidence shifted toward sham-controlled stimulation plus task-focused training outcomes.

In the months covered, a sham-controlled study reported that five sessions of cerebello-spinal direct current stimulation (csDCS, a low-level electrical stimulation applied through the scalp) given during gait training improved Timed Up and Go, SARA (Scale for the Assessment and Rating of Ataxia, a standard ataxia severity score), and miniBEST more than sham stimulation. The report did not describe how long the changes lasted after the sessions ended. Earlier in 2026, a small randomized substudy found that home aerobic exercise modestly improved step length compared with balance training, while other gait features did not clearly differ. Other training studies suggested that practice-based programs can improve specific practiced tasks (for example, walking speed or functional mobility, or certain memory measures) without clearly changing overall ataxia severity over short follow-up. Separately, non-invasive rTMS (repetitive transcranial magnetic stimulation, magnetic pulses applied to the scalp) in SCA3 was linked to EEG (electroencephalogram, a test of brain electrical activity) changes versus sham that predicted later symptom improvement. Overall, these reports suggest that short-term changes are most often seen in targeted mobility and balance measures, and results may depend on the exact program and how consistently it is followed.

Research covered in: January 2026, February 2026, March 2026, April 2026

Cohorts and reviews clarified yield, thresholds, and testing pitfalls.

Beginning in May 2026, multiple adult cohorts reported that an FGF14 repeat expansion (an abnormally long repeated DNA sequence) explains a meaningful share of otherwise unexplained later-onset ataxia. These reports also noted that some standard genetic methods can miss this repeat type. That made repeat-focused methods (including long-read approaches, which read long stretches of DNA in one piece, in some reports) important for detection. Across studies, repeat-size thresholds were emphasized for interpreting how predictive a result is. In several cohorts, repeat length did not consistently correlate with severity or age at onset. From June to September, larger syntheses and real-world cohorts further firmed up the typical SCA27B symptom pattern, including common gait and eye-movement problems. They also showed that stepwise testing pathways (repeat expansions first, then panels/exome) can increase diagnostic yield, including an updated repeat-expansion panel that identified SCA27B in a small late-onset ataxia cohort. In practical terms, these findings can affect how quickly a genetic explanation is found and which test types may be needed when earlier testing is negative or unclear.

Research covered in: May 2026, June 2026, August 2026, September 2026

More studies linked MRI and biomarkers to severity and change.

Across the months covered, several studies reported that MRI (magnetic resonance imaging, detailed pictures of the brain) measures can be more sensitive than standard ataxia scoring in some settings, such as READISCA in SCA1 and SCA3. This supported using MRI outcomes and helped inform sample-size estimates, rather than shortening follow-up. Other tracking signals also appeared. In SCA3, longitudinal measurements of polyQ-expanded ATXN3 in CSF (cerebrospinal fluid, the fluid around the brain and spinal cord) were higher at baseline in symptomatic participants and then declined over repeated measurements. In SCA27B and SCA3, certain repeat patterns or imaging indices such as DTI-ALPS (a diffusion MRI index related to fluid movement along brain vessels) were linked to faster worsening in observational follow-up subsets. Patient-reported and digital measures also advanced, including PROM-Ataxia (a patient questionnaire about ataxia impact) showing a small average 1-year change with wide person-to-person variability, wearable or sensor approaches (for example, presymptomatic SCA2 gait measures and SCA3 balance insoles), and multicenter support for a prism-adaptation learning score (a measure of motor learning using visual shift goggles) as consistent across sites. For now, these tools mainly influence how research studies and trials measure change, and it is still uncertain which ones will best predict an individual person's course or become routine in clinics.

Research covered in: January 2026, February 2026, March 2026, April 2026, May 2026, June 2026, July 2026, August 2026, September 2026

Reports broadened focus to pain, vision, mood, cognition, and autonomic symptoms.

In the months covered, several reports emphasized that symptoms beyond balance can be prominent and measurable. This was especially noted in SCA3. In a single-center cohort, peripheral nerve symptom burden (symptoms from nerve damage outside the brain and spinal cord) was related to worse ataxia and daily function, and autonomic symptom burden (problems with automatic body functions like blood pressure and digestion) was related to lower quality of life. Symptom-focused interventions were mostly early. One SCA3 case report described eight weeks of neuropathic pain relief after scrambler therapy (a device-based treatment that uses electrical signals to change pain signaling). A small human experiment found that rhythm cues shortened speech initiation time but slowed speaking rate. Other clinic-based and subtype-focused studies documented non-motor symptoms such as vision-related daily-life impact. In one report, gaze-evoked nystagmus (involuntary eye movements triggered by looking to the side) was linked to worse vision-related quality of life. In adult-onset ataxia clinic records, mood disorders, cognitive impairment, and pain were commonly documented, and depression and anxiety were recorded more often in SCA than in non-SCA ataxias. Overall, these findings highlight that day-to-day impact often includes pain, vision, mood, cognition, and autonomic features, while the supportive approaches studied so far range from single-patient reports to small experiments.

Research covered in: January 2026, February 2026, June 2026, July 2026, August 2026, September 2026